
Liangxian Cao

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6213803/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Self-renewal as a therapeutic target in human colorectal cancer. Nature Medicine, 2014, 20, 29-36.	30.7	438
2	BMI1 as a novel target for drug discovery in cancer. Journal of Cellular Biochemistry, 2011, 112, 2729-2741.	2.6	127
3	Targeting of Hematologic Malignancies with PTC299, A Novel Potent Inhibitor of Dihydroorotate Dehydrogenase with Favorable Pharmaceutical Properties. Molecular Cancer Therapeutics, 2019, 18, 3-16.	4.1	65
4	The DHODH inhibitor PTC299 arrests SARS-CoV-2 replication and suppresses induction of inflammatory cytokines. Virus Research, 2021, 292, 198246.	2.2	53
5	BMI-1 Targeting Interferes with Patient-Derived Tumor-Initiating Cell Survival and Tumor Growth in Prostate Cancer. Clinical Cancer Research, 2016, 22, 6176-6191.	7.0	49
6	Targeted BMI1 inhibition impairs tumor growth in lung adenocarcinomas with low CEBPα expression. Science Translational Medicine, 2016, 8, 350ra104.	12.4	45
7	Evaluating the Mechanism and Therapeutic Potential of PTC-028, a Novel Inhibitor of BMI-1 Function in Ovarian Cancer. Molecular Cancer Therapeutics, 2018, 17, 39-49.	4.1	40
8	Effective Delivery of a Microtubule Polymerization Inhibitor Synergizes with Standard Regimens in Models of Pancreatic Ductal Adenocarcinoma. Clinical Cancer Research, 2019, 25, 5548-5560.	7.0	23
9	Discovery of Novel Small Molecule Inhibitors of VEGF Expression in Tumor Cells Using a Cell-Based High Throughput Screening Platform. PLoS ONE, 2016, 11, e0168366.	2.5	18
10	Phase 1 Study of Safety, Tolerability, and Pharmacokinetics of PTC299, an Inhibitor of Stressâ€Regulated Protein Translation. Clinical Pharmacology in Drug Development, 2016, 5, 296-305.	1.6	16
11	Inhibition of BMI1, a Therapeutic Approach in Endometrial Cancer. Molecular Cancer Therapeutics, 2018, 17, 2136-2143.	4.1	15
12	Preclinical and Early Clinical Development of PTC596, a Novel Small-Molecule Tubulin-Binding Agent. Molecular Cancer Therapeutics, 2021, 20, 1846-1857.	4.1	13
13	Emvododstat, a Potent Dihydroorotate Dehydrogenase Inhibitor, Is Effective in Preclinical Models of Acute Myeloid Leukemia. Frontiers in Oncology, 2022, 12, 832816.	2.8	5